**Megan Stevens MD** 

## Parkinson's Disease

### Objectives

Tremor types	1
Diagnostic process	2
Parkinson's Disease	3
PD treatments	4
What else might it be?	5

A patient presents in clinic with tremor, worried about Parkinson's Disease..

# What is Parkinson's Disease?






#### **James Parkinson 1817**

P.A. Lewis / A Short Biography of James Parkinson

183







Paralysis Agitans. (After St. Leger.)

Journal of Parkinson's Disease 2 (2012) 181–187

DOI 10.3233/JPD 2012-012108

IOS Press

Fig. 2. James Parkinson's legacy to the field of neurology (A) The frontispiece to his essay on the Shaking Palsy, written in 18 illustration of an individual with Parkinson's disease from William Gower's work Manual of the Diseases of the Nervous System written in 1886.



#### 4 cardinal features

ON THE

SHAKING PALSY.

FOR SHEEWGOD, NEELY, AND JONES, FATERMOTER BOW.

P.A. Lewis / A Short Biography of James Parkinson

Postural instability
Pill rolling rest tremor

Bradykinesia

**Rigidity** 




Paralysis Agitans. (After St. Leger.)

Journal of Parkinson's Disease 2 (2012) 181–187 DOI 10.3233/JPD 2012-012108 IOS Press

183

Fig. 2. James Parkinson's legacy to the field of neurology (A) The frontispiece to his essay on the Shaking Pai illustration of an individual with Parkinson's disease from William Gower's work *Manual of the Diseases of the Nervous System* written in 1886.



#### Lewy body


- intraneuronal
- cytoplasmic
- alpha synuclein fibril (Fredrick Lewy 1912)





#### Substantia nigra

In 1919 Konstantin **Tretiakoff shows** loss of substantia nigra (AKA dopaminergic neurons) in PD patients





## Levodopa shown to improve PD symptoms in published study

Cotzias GC (March 1968). "L-Dopa for Parkinsonism". The New England Journal of Medicine. 278 (11): 630.

Back to our patient, we need to evaluate the tremor



#### Involuntary Oscillatory Rhythmic

Most common movement disorder seen by PCP



## Tremor types



**Rest - no voluntary contraction Action - voluntary contraction** Postural - against gravity Isometric - against rigid stationary **Kinetic - with movement** Intention - targeted movement Task specific - self explanatory





#### **Tremor descriptors**

#### Parkinson disease

- Asymmetric
- Rest
- High amplitude
- Slow frequency 3-5HZ/4-6Hz
- resolves with muscle activation

#### Physiologic tremor

- Symmetric
- Invariable
- Low amplitude
- High frequency 8-12 Hz
- Increased by caffeine and stress

#### **Essential tremor**

- Symmetric
- Kinetic
- Mid amplitude
- Mid frequency 5-8Hz
- Alcohol dampens it



## Diagnostic process: beyond the tremor



Onset Better/worse Family hx **Anosmia? Gait change?** micrographia sleep issues

Slowly progressive **Better with activation Not usually Yes**\*\*\* Shuffling/stooped yes

and Garaschuk, 2023

Berg et al., 2015; Iannilli et al., 2017; Slabik

yes









#### **Medication list review**

Antipsychotics 1st
Haloperidol
Droperidol
Fluphenazine
Pimozide
Perphenazine

Antipsychotics 2nd Risperidone Olanzapine Aripiprazole Lurasidone Clozapine Ziprasidone Quetiapine

Other
Tetrabenazine
Reserpine
Prochlorperazine
Metaclopramide
Valproic acid

6-12 month wash out



drooling



#### **Review of systems**

**Depression Anxiety** Constipation **Change in memory Weight loss Anemia Soft voice** Illegible handwriting **RLS** 

**Seborrheic dermatitis Acting out dreams** Insomnia **Daytime sleepiness Fatigue** Loss of smell **Shoulder pain** DM2, HTN, cancer **Urinary problems** 

Santiago JA et.al. Biological and Clinical Implications of Comorbidities in Parkinson's Disease Front Aging

Neurosci 2017: 0: 304

Multiorgan α-synuclein deposits in Parkinson's disease

Postmortem

Stellate ganglion

Paravertebral sympathetic Ganglia

Vagus nerve


Epicardial plexus

Mesenteric sympathetic ganglia

Enteric nervous system

Adrenal gland

Genitourinary tract



Surguchov A. Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma. *Brain Sciences*. 2016; 6(2):17. https://doi.org/10.3390/brainsci6020017

Multiorgan α-synuclein deposits in Parkinson's disease

Postmortem

Stellate ganglion

Paravertebral sympathetic Ganglia

Vagus nerve


Epicardial plexus

Mesenteric sympathetic ganglia


Enteric nervous system


Adrenal gland

Genitourinary tract



Surguchov A. Parkinson **hyperhydros s**ylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanchus Parkinson (2001). 17. https://doi.org/10.3390/brainsci6020017









#### camptocormia







#### **Shuffling gait**







#### retropulsion



A systematic review American Academy of Neurology (AAN) 2006:
levodopa or apomorphine challenge tests for DX could help BUT 30% with negative challenge have it 20-30% with a positive test have alternate Dx



### Medication trial of at least 1,000mg levodopa daily for 2 months

Carbidopa/levodopa 25mg/100mg tabs
Work up to 1 tab 3 times a day at 8am
noon and 4
Increase to 1.5 tabs 3 x a day the
following week
Increase to 2 tabs 3 x a day the following
week





#### Med associated dyskinesia






#### **Imaging**

SDH
Hydrocephalus
Stroke
BG calcifications







#### **Brain MRI**






McFarland NR, Hess CW. Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches. Semin Neurol. 2017 Apr;37(2):215-227. doi: 10.1055/s-0037-1602422. Epub 2017 May 16. PMID: 28511262; PMCID: PMC5961706.





### Dat scan can differentiate Parkinson's and Parkinson's plus from controls





#### skin biopsy for alpha synucleinopathies





Malfertheiner, K et.al. The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders Front. Neurol., 04 October 2021 Sec. Movement Disorders Volume 12 - 2021



## EVALUATION with MOVEMENT DISORDER SPECIALIST

Dr Ellen Valadez



## Parkinson's disease

#### Movement Disorder Society clinical diagnostic criteria for Parkinson Disease – Executive summary/completion form

The first essential criterion is parkinsonism, which is defined as bradykinesia, in combination with at least one of rest tremor or rigidity. Examination of all cardinal manifestations should be carried out as described in the MDS-Unified Parkinson Disease Rating Scale. Once parkinsonism has been diagnosed:

#### Diagnosis of clinically established PD requires:

- 1. Absence of absolute exclusion criteria
- 2. At least two supportive criteria, and
- 3. No red flags

#### Diagnosis of clinically probable PD requires:

- 1. Absence of absolute exclusion criteria
- 2. Presence of red flags counterbalanced by supportive criteria
  If one red flag is present, there must also be at least one supportive criterion
  If two red flags, at least two supportive criteria are needed
  No more than two red flags are allowed for this category

# MDS critieria

#### Supportive criteria (check box if criteria met)

- 1. Clear and dramatic beneficial response to dopaminergic therapy. During initial treatment, patient returned to normal or near-normal level of function. In the absence of clear documentation of initial response a dramatic response can be classified as:
  - a. Marked improvement with dose increases or marked worsening with dose decreases. Mild changes do not qualify. Document this either objectively (>30% in UPDRS III with change in treatment), or subjectively (clearly-documented history of marked changes from a reliable patient or caregiver)
  - b. Unequivocal and marked on/off fluctuations, which must have at some point included predictable end-of-dose wearing off
- 2. Presence of levodopa-induced dyskinesia
- 3. Rest tremor of a limb, documented on clinical examination (in past, or on current examination)
- 4. The presence of either olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy





#### Let's break it down

BRADYKINESIA +
resting tremor
OR
BRADYKINESIA +
rigidity







### **Supportive features**

- 1) Improvement in either rigidity, tremor or bradykinesia on levodopa
- 2) Levodopa associated dyskinesias
- 3) Unilateral rest tremor
- 4) olfactory function loss
- 5) denervation of cardiac sympathetic function on MIBG scan

And no red flags...

# PD treatments



First line: Carbidopa-levodopa take with carbs not protein watch for nausea, OH Dopamine agonists, ropinirole, pramipexole younger patients at high risk for dyskinesias watch for las vegas syndrome/sleepiness MAO-B selegiline, rasagiline once daily, milder benefit Amantadine useful for prominent tremor, milder benefit Anticholinergics trihexyphenidyl, benztropine milder benefit, cognitive side effects





#### **Other treatments**

PT, OT, ST Big and Loud therapy

Levodopa through J tube

**DBS** 

**Keep up nutrition!** 







## **Treating more than tremor**

Orthostatic hypotension midodrine droxidopa

**Dementia donepezil** 

**Depression SSRIs** 

**RBD** melatonin and clonazepam

# What else might it be?



Rapid gait impairment /wheelchair in 1<sup>st</sup> 5 years (PSP)

No progression in motor symptoms in 1<sup>st</sup> 5 years

**Bulbar dysfunction (PSP)** 

Severe autonomic features in 1st 5 years (MSA)

Recurrent falls in 1<sup>st</sup> 3 years(PSP)



Inspiratory sighs/stridor (MSA)

anterocollis and /or contractures in feet and hands in 1<sup>st</sup> 10 years (dystonia, MSA)


No associated sleep issues, autonomic issues, or psychiatric issues in 1<sup>st</sup> 5 years

pyramidal signs/weakness hyperreflexia

Symmetric involvement

# RED FLAGS

Anterocollis present in 42% with MSA 5.8% PD



Doherty KM, Gershanik OS, Bloem BR. Postura. deformities in Parkinson's disease. *Lancet Neurol* 2011;10:538–549

# Exclusionary

cerebellar signs downward vertical gaze palsy (PSP) probable FTD or PPA lower limbs only for 3 years (vascular) **DA** depleting med in last year no response to levodopa cortical sensory loss or ideomotor apraxia (CBD) normal DAT scan alternative dx deemed more likely by expert



## **PARKINSON PLUS**

Lewy body dementia	Multiple system atrophy (MSA)	Progressive supranuclear	Corticobasal ganglionic
(LBD)	muluple system au opny (msA)	palsy (PSP)	degeneration (CBD)
Parkinsonism plus	Parkinsonism plus	Parkinsonism plus	Parkinsonism plus
synuclein	synuclein	tau	tau
Early dementia	Early autonomic dysfunction:	Downgaze     impairment	Asymmetry
Hallucinations	Orthostatic hypotension	Ophthalmoplegia  • Axial rigidity	Apraxia
Neuroleptic	Erectile dysfunction		Alien limb
sensitivity		Other brainstem	Cortical sensory
Fluctuating	Incontinence	symptoms: dysphagia, oral dyskinesia,	loss
cognition	Cognition preserved https://youtu.be/ek	dysphonia	

Toxic MPTP, manganese, carbon monoxide **Metabolic Hypoparathyroidism Liver failure Extrapontine myelinolysis ESRD** with DM DM2 Infectious HIV, neurosyphilis, prion disease, PML, toxo drug induced (DA antagonists) vascular structural-cSDH, tumor, head trauma, **NPH** genetic- Wilson's



#### If you are looking for more information:

Marino BLB, de Souza LR, Sousa KPA, Ferreira JV, Padilha EC, da Silva CHTP, Taft CA, Hage-Melim LIS. Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini Rev Med Chem. 2020;20(9):754-767. doi: 10.2174/1389557519666191104110908. PMID: 31686637.

